4.8 Article

Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies

Journal

LANCET
Volume 388, Issue 10043, Pages 465-475

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0140-6736(16)30467-6

Keywords

-

Funding

  1. Population Health Research Institute
  2. Canadian Institutes of Health Research
  3. Heart and Stroke Foundation of Ontario, Canada
  4. AstraZeneca (Sweden, Canada, Turkey)
  5. Sanofi-Aventis (France, Canada, Turkey)
  6. Boehringer Ingelheim (Germany)
  7. Boehringer Ingelheim (Canada)
  8. Servier
  9. GlaxoSmithKline
  10. Novartis
  11. King Pharma
  12. Bangladesh Independent University and Mitra and Associates, Bangladesh
  13. Unilever Health Institute, Brazil
  14. Public Health Agency of Canada
  15. Champlain Cardiovascular Disease Prevention Network, Canada
  16. Universidad de la Frontera, Chile
  17. National Center for Cardiovascular Diseases, China
  18. Colciencias, Colombia [6566-04-18062]
  19. Indian Council of Medical Research, India
  20. Ministry of Science, Technology and Innovation, Malaysia [07-05-IFN-MEB010]
  21. Ministry of Higher Education, Malaysia [600-RMI/LRGS/5/3]
  22. Universiti Kebangsaan Malaysia, Malaysia [UKM-Hejim-Komuniti-15-2010]
  23. Ministry of Science and Higher Education, Poland [290/W-PURE/2008/0]
  24. Wroclaw Medical University, Poland
  25. North-West University, South Africa
  26. South Africa Netherlands Research Programme on Alternatives in Development (SANPAD)
  27. National Research Foundation
  28. Medical Research Council of South Africa
  29. South Africa Sugar Association (SASA), South Africa
  30. Faculty of Community and Health Sciences (UWC), South Africa
  31. Council for Working Life and Social Research, Sweden
  32. Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning, Sweden
  33. Swedish Heart and Lung Foundation, Sweden
  34. Swedish Research Council
  35. Swedish State under LUA (LakarUtbildningsAvtalet)
  36. Vastra Gotaland Region (FOUU), Sweden
  37. Metabolic Syndrome Society
  38. Sheikh Hamdan Bin Rashid Al Maktoum Award For Medical Sciences
  39. Dubai Health Authority, Dubai, the United Arab Emirates
  40. Sanofi-Aventis Global
  41. Sanofi Aventis Canada
  42. Genome Quebec Innovation Centre
  43. Heart and Stroke Foundation of Canada
  44. Boehringer Ingelheim

Ask authors/readers for more resources

Background Several studies reported a U-shaped association between urinary sodium excretion and cardiovascular disease events and mortality. Whether these associations vary between those individuals with and without hypertension is uncertain. We aimed to explore whether the association between sodium intake and cardiovascular disease events and all-cause mortality is modified by hypertension status. Methods In this pooled analysis, we studied 133 118 individuals (63 559 with hypertension and 69 559 without hypertension), median age of 55 years (IQR 45-63), from 49 countries in four large prospective studies and estimated 24-h urinary sodium excretion (as group-level measure of intake). We related this to the composite outcome of death and major cardiovascular disease events over a median of 4.2 years (IQR 3.0-5.0) and blood pressure. Findings Increased sodium intake was associated with greater increases in systolic blood pressure in individuals with hypertension (2.08 mm Hg change per g sodium increase) compared with individuals without hypertension (1.22 mm Hg change per g; p(interaction) < 0.0001). In those individuals with hypertension (6835 events), sodium excretion of 7 g/day or more (7060 [11%] of population with hypertension: hazard ratio [HR] 1.23 [95% CI 1.11-1.37]; p < 0.0001) and less than 3 g/day (7006 [11%] of population with hypertension: 1.34 [1.23-1.47]; p < 0.0001) were both associated with increased risk compared with sodium excretion of 4-5 g/day (reference 25% of the population with hypertension). In those individuals without hypertension (3021 events), compared with 4-5 g/day (18 508 [27%] of the population without hypertension), higher sodium excretion was not associated with risk of the primary composite outcome (>= 7 g/day in 6271 [9%] of the population without hypertension; HR 0.90 [95% CI 0.76-1.08]; p = 0.2547), whereas an excretion of less than 3 g/day was associated with a significantly increased risk (7547 [11%] of the population without hypertension; HR 1.26 [95% CI 1.10-1.45]; p = 0.0009). Interpretation Compared with moderate sodium intake, high sodium intake is associated with an increased risk of cardiovascular events and death in hypertensive populations (no association in normotensive population), while the association of low sodium intake with increased risk of cardiovascular events and death is observed in those with or without hypertension. These data suggest that lowering sodium intake is best targeted at populations with hypertension who consume high sodium diets.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available